Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natrecor Labeling Revised To Include Expanded Mortality Analysis

Executive Summary

Johnson & Johnson/Scios' Natrecor (nesiritide) labeling has been revised to include an expanded analysis of the mortality rates seen in pivotal trials of the congestive heart failure agent
Advertisement

Related Content

FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article
FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article
Medicare Outpatient Coverage Of Natrecor Could Be Limited To Clinical Trials
Medicare Outpatient Coverage Of Natrecor Could Be Limited To Clinical Trials
J&J Natrecor “Dear Doctor” Letter Advises Against Outpatient Use
Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues
Tysabri Return Depends On Patient Group Input, CDER Deputy Says
Drug Safety Board Will Lead To More Advisory Cmte. Meetings – FDA’s Galson
J&J Buys Scios: Will Natrecor Make Another Centocor?
J&J Buys Scios: Will Natrecor Make Another Centocor?

Topics

Advertisement
UsernamePublicRestriction

Register

PS045718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel